ArticleFrontiers in medicine2024
Long-term prognosis in patients with thymoma combined with myasthenia gravis: a propensity score-matching analysis.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Preoperative Myasthenia Gravis and Five-Year Outcomes After Thymoma Resection: A Multicenter Cohort Study.Annals of surgical oncology · 2026Article
- Myasthenia Gravis and Thymoma.Muscle & nerve · 2026Review
- Machine Learning-Based Risk Assessment of Myasthenia Gravis Onset in Thymoma Patients and Analysis of Their Correlations and Causal Relationships.Journal of imaging informatics in medicine · 2026Article
- Advanced Masaoka-Koga stage as an independent predictor of thymoma recurrence after complete resection: myasthenia gravis was not an independent factor.Gland surgery · 2025Article
- Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience.Frontiers in immunology · 2025Article
- Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We aimed to assess the impact of myasthenia gravis (MG) on the long-term prognosis in patients with thymoma after surgery and identify related prognostic factors or predictors. Methods: This retrospective observational study included 509 patients with thymoma (thymoma combined with MG [MG group] and thymoma alone [non-MG group]). Propensity score matching was performed to obtain comparable subsets of 96 patients in each group. A comparative analysis was conducted on various parameters. Results: Before matching, the 10-year survival and recurrence-free survival rates in both groups were 93.8 and 98.4%, and 85.9 and 93.4%, respectively, with no statistically significant difference observed in the survival curves between the groups ( Conclusion: There was no difference in prognosis in patients with thymoma with or without MG. The Masaoka-Koga stage has emerged as an independent prognostic factor affecting recurrence-free survival in patients with thymoma, while postoperative adjuvant therapy represents a poor prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.